Clin Cancer Res: The 3-year follow-up survival results of the ATTRACTION-3 study show that nivolumab improves the prognosis of patients with advanced esophageal squamous cell carcinoma (ESCC) compared with chemotherapy

ATTRACTION-3 is a randomized, multicenter, open-label phase III clinical study comparing the PD-1 inhibitor nivolu mab ( navoluumab ) in previously treated patients with advanced esophageal squamous cell carcinoma (ESCC).
anti) and chemotherapy (paclitaxel or docetaxel) treatment .

After a median follow-up of 17.

6 months, the study reported a median overall survival (OS) of 10.

ATTRACTION-3 is a randomized, multicenter, open-label phase III clinical study comparing the PD-1 inhibitor nivolu mab ( navoluumab ) in previously treated patients with advanced esophageal squamous cell carcinoma (ESCC).
anti) and chemotherapy (paclitaxel or docetaxel) treatment .

Between January 7, 2016, and May 25, 2017, 590 patients were evaluated and 419 patients were randomly assigned to treatment: 210 received nivolu mab and 209 received chemotherapy
.

The response evaluable population included 329 patients ( nivolu mab, n = 171; chemotherapy, n = 158) and the safety population included 417 patients ( nivolu mab, n = 209; chemotherapy, 208)

Between January 7, 2016, and May 25, 2017, 590 patients were evaluated and 419 patients were randomly assigned to treatment: 210 received nivolu mab and 209 received chemotherapy

At the clinical cutoff time (May 25, 2020), the minimum follow-up period was 36.

The ORR was 19.
3% and 21.
5% in the nivolumab group and 21.
5% in the chemotherapy group; DCR was 37.
4% and 62.
7%, respectively; the median DOR (95% CI) was 6.
9 (5.
4 11.
1) months and 3.
9 (2.
8–4.
2) months, respectively month
.

 

The ORR was 19.

Median OS for CR/PR, SD, and PD was 19.
9 vs.
15.
4 months (HR [95% CI], 0.
84 [0.
46 1.
54]), 17.
4 vs.
8.
8 months (HR [95% CI], 0.
84 [0.
46 1.
54]), 17.
4 vs.
[95% CI], 0.
41 [0.
23 0.
71]), and 7.
6 vs.
4.
2 months (HR [95% CI], 0.
59 [0.
39 318 0.
88])
.

Median OS for CR/PR, SD, and PD was 19.
9 vs.
15.
4 months (HR [95% CI], 0.
84 [0.
46 1.
54]), 17.
4 vs.
8.
8 months (HR [95% CI], 0.
84 [0.
46 1.
54]), 17.
4 vs.
[95% CI], 0.
41 [0.
23 0.
71]), and 7.
6 vs.
4.
2 months (HR [95% CI], 0.
59 [0.
39 318 0.
88])
.

Median OS for CR/PR, SD, and PD was 19.

Reasons for discontinuation (Nivolumab vs.
chemotherapy) were disease progression [140 (67.
0%) vs.
138 (66.
3%)], AEs [16 (7.
7%) vs.
8 (3.
8%)], physician judgment [17 (8.
1%)] %) vs.
27 (13.
0%)] and other reasons [21 (10.
0%) vs.
19 (9.
1%)]
.

Subsequent therapy was administered to 127 of 210 patients (60.

Reasons for discontinuation (Nivolumab vs.

TRAEs of any grade were reported in 138 (66.

In conclusion, studies have shown that second-line treatment with nivolumab (nivolumab) improves the prognosis of patients with advanced esophageal squamous cell carcinoma (ESCC) compared with chemotherapy

Original source:

Original source:

Okada M, Kato K, Cho BC, Takahashi M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Matsumura Y , Takazawa A, Kitagawa Y.
Three-year follow-up and response-survival relationship of nivolumab in previously treated patients with advanced esophageal squamous cell carcinoma (ATTRACTION-3).
Clin Cancer Res.
2022 Mar 16:clincanres.
0985.
2021.
doi: 10.
1158/1078-0432.
CCR-21-0985.
Epub ahead of print.
PMID: 35294546.

Okada M, Kato K, Cho BC, Takahashi M, Lin CY, Chin K, Kadowaki S, Ahn MJ, Hamamoto Y, Doki Y, Yen CC, Kubota Y, Kim SB, Hsu CH, Holtved E, Xynos I, Matsumura Y , Takazawa A, Kitagawa Y.
Three-year follow-up and response-survival relationship of nivolumab in previously treated patients with advanced esophageal squamous cell carcinoma (ATTRACTION-3).
Clin Cancer Res.
2022 Mar 16:clincanres.
0985.
2021.
doi: 10.
1158/1078-0432.
CCR-21-0985.
Epub ahead of print.
PMID: 35294546.
Leave a message here